Betting big on quantitative neurobiomarkers
- Introducing Beacon Biosignals: a neurotechnology company founded to develop machine learning-enabled EEG neurobiomarkers and accelerate precision medicine for any disease state affecting the brain
- Founded by MD/PhDs and engineers from Harvard and MIT, Beacon is propelled by the vision of a computing platform designed to scale the interrogation of large brain datasets with unprecedented throughput & capability
- Beacon’s EEG neurobiomarker platform is engineered to accelerate clinical trials and enable new treatments for patients with neurological & psychiatric disease
Introducing Beacon Biosignals: a neurotechnology company founded to develop machine learning-enabled EEG neurobiomarkers and accelerate precision medicine for any disease state affecting the brain.
In the precision medicine era, diagnostics have become integral to the development of novel therapeutics. Oncology has led the way with molecular diagnostics supporting an explosion of investment and innovation in targeted therapeutics. We believe neuroscience is next. At the 2020 J.P. Morgan Conference, Roche CEO Bill Anderson noted “We think neuroscience has the potential to be in the `20s what oncology has been in the last decade.” At Beacon Biosignals, our thesis is that EEG will drive this change and accelerate precision medicine for any disease state affecting the brain, including disorders spanning neurology, psychiatry, and sleep.
I am thrilled to announce that Beacon Biosignals is emerging from stealth with an oversubscribed $27M Series A financing led by General Catalyst and with participation from Casdin Capital and Beacon’s seed angels. Beacon was founded in 2019 with vision of a computing platform designed to scale the interrogation of large brain datasets with unprecedented throughput and capability. The range of use cases is endless, so how do we envision creating impact? Our focus is on partnering with the most cutting-edge novel therapeutic partnering with the most cutting edge science is how we drive impact. Beacon is dedicated to helping our biopharma partners accelerate novel therapeutics to reach patients with significant unmet need.
We are betting big on EEG neurobiomarkers, because we believe three big developments are about to converge:
- The rise of scalable machine learning
- Increasing recognition of quantitative neurobiomarkers
- A surge in development of precision medicines for the brain